0001179110-17-010236.txt : 20170707
0001179110-17-010236.hdr.sgml : 20170707
20170707212952
ACCESSION NUMBER: 0001179110-17-010236
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170705
FILED AS OF DATE: 20170707
DATE AS OF CHANGE: 20170707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics Plc
CENTRAL INDEX KEY: 0001703287
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 6108166640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Plc
DATE OF NAME CHANGE: 20170407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HBM Healthcare Investments (Cayman) Ltd.
CENTRAL INDEX KEY: 0001232258
STATE OF INCORPORATION: E9
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38132
FILM NUMBER: 17956221
BUSINESS ADDRESS:
STREET 1: 2454 WEST BAY ROAD, 3RD FLOOR
CITY: GRAND CAYMAN
STATE: E9
ZIP: 00000
BUSINESS PHONE: 1 345 946 8002
MAIL ADDRESS:
STREET 1: P.O BOX 30852
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1204
FORMER NAME:
FORMER CONFORMED NAME: HBM BIOVENTURES CAYMAN LTD
DATE OF NAME CHANGE: 20030512
4
1
edgar.xml
FORM 4 -
X0306
4
2017-07-05
0
0001703287
Nabriva Therapeutics Plc
NBRV
0001232258
HBM Healthcare Investments (Cayman) Ltd.
GOVERNORS SQUARE, SUITE #4-212-2
23 LIME TREE BAY AVE., WEST BAY
GRAND CAYMAN
E9
00000
CAYMAN ISLANDS
0
0
1
0
Ordinary Shares
2017-07-05
4
S
0
2562
10.5232
D
2569315
D
Ordinary Shares
2017-07-07
4
S
0
133
10.50
D
2569182
D
On June 23, 2017, Nabriva Therapeutics plc ("Nabriva plc") became the successor of Nabriva Therapeutics AG ("Nabriva AG") pursuant to an exchange offer. Pursuant to the exchange offer, each outstanding common share of Nabriva AG was exchanged for ten ordinary shares of Nabriva plc and each outstanding American Depositary Share of Nabriva AG, which represented one-tenth of one common share of Nabriva AG, was exchanged for one ordinary share of Nabriva plc. On prior reports filed by the reporting person subsequent to the completion of the exchange offer, all references to American Depositary Shares of Nabriva AG should be understood to refer to ordinary shares of Nabriva plc..
The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.50 to $10.74 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
/s/ Jean-Marc Lesieur, Director
2017-07-07